Harry Shi

6.8k total citations · 2 hit papers
56 papers, 4.6k citations indexed

About

Harry Shi is a scholar working on Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine and Rheumatology. According to data from OpenAlex, Harry Shi has authored 56 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Endocrinology, Diabetes and Metabolism, 20 papers in Cardiology and Cardiovascular Medicine and 14 papers in Rheumatology. Recurrent topics in Harry Shi's work include Hormonal Regulation and Hypertension (14 papers), Rheumatoid Arthritis Research and Therapies (14 papers) and Blood Pressure and Hypertension Studies (11 papers). Harry Shi is often cited by papers focused on Hormonal Regulation and Hypertension (14 papers), Rheumatoid Arthritis Research and Therapies (14 papers) and Blood Pressure and Hypertension Studies (11 papers). Harry Shi collaborates with scholars based in United States, United Kingdom and France. Harry Shi's co-authors include Faı̈ez Zannad, Henry Krum, Dirk J. van Veldhuisen, Karl Swedberg, John J.V. McMurray, John Vincent, Bertram Pitt, Stuart Pocock, Steven E. Nissen and Paul M. Thompson and has published in prestigious journals such as New England Journal of Medicine, JAMA and Circulation.

In The Last Decade

Harry Shi

54 papers receiving 4.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms

2010 2.0k citations Faı̈ez Zannad, John J.V. McMurray et al. New England Journal of Medicine profile →
Effect of Antihypertensive Agents on Cardiovascular Events in Patients With Coronary Disease and Normal Blood Pressure

2004 769 citations Steven E. Nissen, E. Murat Tuzcu et al. JAMA profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Harry Shi United States	23	3.1k	1.9k	1.1k	905	541	56	4.6k
Aimun Ahmed United Kingdom	8	3.5k 1.2×	1.3k 0.7×	1.1k 1.0×	1.2k 1.3×	782 1.4×	19	7.0k
Yves Lacourcière Canada	38	3.8k 1.2×	1.5k 0.8×	916 0.9×	654 0.7×	378 0.7×	148	5.2k
Marjorie Gatlin United States	10	4.0k 1.3×	3.1k 1.6×	821 0.8×	1.3k 1.5×	748 1.4×	16	5.7k
Roberto Pontremoli Italy	42	2.5k 0.8×	1.4k 0.8×	802 0.8×	810 0.9×	659 1.2×	214	5.6k
Marc A. Pohl United States	20	3.3k 1.1×	2.4k 1.3×	1.4k 1.3×	838 0.9×	471 0.9×	31	6.5k
Richard M. Bittman United States	10	3.1k 1.0×	2.4k 1.3×	833 0.8×	1.5k 1.6×	622 1.1×	15	4.9k
Tara I. Chang United States	34	2.6k 0.9×	677 0.4×	911 0.9×	1.3k 1.4×	320 0.6×	132	5.2k
Jay H. Kleiman United States	14	3.8k 1.2×	2.9k 1.5×	965 0.9×	1.4k 1.6×	736 1.4×	20	5.5k
J Widimský Czechia	35	2.6k 0.8×	2.0k 1.1×	1.1k 1.1×	1.8k 2.0×	281 0.5×	328	5.1k
Barbara Roniker United States	16	4.0k 1.3×	3.9k 2.1×	1.2k 1.1×	1.6k 1.8×	958 1.8×	20	6.2k

Countries citing papers authored by Harry Shi

Since Specialization

Citations

This map shows the geographic impact of Harry Shi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harry Shi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harry Shi more than expected).

Fields of papers citing papers by Harry Shi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Harry Shi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harry Shi. The network helps show where Harry Shi may publish in the future.

Co-authorship network of co-authors of Harry Shi

This figure shows the co-authorship network connecting the top 25 collaborators of Harry Shi. A scholar is included among the top collaborators of Harry Shi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harry Shi. Harry Shi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dong, Yuan, Wenbo Xu, Faisal Raza, et al.. (2024). Baicalein Long‐Circulating Liposomes Improve Histological and Functional Outcomes After Traumatic Brain Injury. Advances in Pharmacological and Pharmaceutical Sciences. 2024(1). 2869332–2869332. 2 indexed citations

Dagogo‐Jack, Samuel, Robert Frederich, Jie Liu, et al.. (2023). Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV. The Journal of Clinical Endocrinology & Metabolism. 108(8). 2042–2051. 2 indexed citations

Fleischmann, R., Boulos Haraoui, Maya H Buch, et al.. (2022). Analysis of Disease Activity Metrics in a Methotrexate Withdrawal Study among Patients with Rheumatoid Arthritis Treated with Tofacitinib plus Methotrexate. Rheumatology and Therapy. 10(2). 375–386. 1 indexed citations

Strand, Vibeke, Jeffrey Kaine, Rieke Alten, et al.. (2020). Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinib. Arthritis Research & Therapy. 22(1). 243–243. 18 indexed citations

Dikranian, Ara, Valderílio Feijó Azevedo, Louis Bessette, et al.. (2018). FREQUENCY AND DURATION OF EARLY NON-SERIOUS ADVERSE EVENTS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TOFACITINIB 5 MG TWICE DAILY AS MONOTHERAPY AND COMBINATION THERAPY. JCR Journal of Clinical Rheumatology. 25. 1 indexed citations

Ferreira, João Pedro, Kévin Duarte, Gilles Montalescot, et al.. (2017). Effect of eplerenone on extracellular cardiac matrix biomarkers in patients with acute ST-elevation myocardial infarction without heart failure: insights from the randomized double-blind REMINDER Study. Clinical Research in Cardiology. 107(1). 49–59. 17 indexed citations

Rossignol, Patrick, Nicolas Girerd, George L. Bakris, et al.. (2016). Impact of Eplerenone on Cardiovascular Outcomes in Heart Failure Patients with Hypokalaemia. European Journal of Heart Failure. 19(6). 792–799. 35 indexed citations

Eschalier, Romain, John J.V. McMurray, Karl Swedberg, et al.. (2013). Safety and Efficacy of Eplerenone in Patients at High Risk for Hyperkalemia and/or Worsening Renal Function. Journal of the American College of Cardiology. 62(17). 1585–1593. 199 indexed citations

Preiss, David, Dirk J. van Veldhuisen, Naveed Sattar, et al.. (2012). Eplerenone and New-Onset Diabetes in Patients with Mild Heart Failure: Results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). European Journal of Heart Failure. 14(8). 909–915. 55 indexed citations

10.

Swedberg, Karl, Faı̈ez Zannad, John J.V. McMurray, et al.. (2012). Eplerenone and Atrial Fibrillation in Mild Systolic Heart Failure. Journal of the American College of Cardiology. 59(18). 1598–1603. 186 indexed citations

11.

Zannad, Faı̈ez, John J.V. McMurray, Helmut Drexler, et al.. (2010). Rationale and Design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF). European Journal of Heart Failure. 12(6). 617–622. 56 indexed citations

12.

Zannad, Faı̈ez, John J.V. McMurray, Henry Krum, et al.. (2010). Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. New England Journal of Medicine. 364(1). 11–21. 2048 indexed citations breakdown →

13.

Li, Jennifer S., Joseph T. Flynn, Ronald J. Portman, et al.. (2010). The Efficacy and Safety of the Novel Aldosterone Antagonist Eplerenone in Children with Hypertension: A Randomized, Double-Blind, Dose-Response Study. The Journal of Pediatrics. 157(2). 282–287. 31 indexed citations

14.

Feldman, Ross D., John M. Flack, Richard Hobbs, et al.. (2009). A Comparison of Blood Pressure and Low-Density Lipoprotein Cholesterol Reduction After Treatment With Single-Pill Amlodipine/Atorvastatin In Elderly (75 years or more) and Younger (less than 75 years) Patients: Results of a Posted Analysis of 5559 Patients. American Journal of Hypertension. 22. 12–12. 1 indexed citations

15.

Flack, John M., Ronald G. Victor, Karol E. Watson, et al.. (2008). Improved Attainment of Blood Pressure and Cholesterol Goals Using Single-Pill Amlodipine/Atorvastatin in African Americans: The CAPABLE Trial. Mayo Clinic Proceedings. 83(1). 35–45. 43 indexed citations

16.

Nissen, Steven E., E. Murat Tuzcu, Peter Libby, et al.. (2004). Effect of Antihypertensive Agents on Cardiovascular Events in Patients With Coronary Disease and Normal Blood Pressure. JAMA. 292(18). 2217–2217. 769 indexed citations breakdown →

17.

Grimm, Richard H., Henry R. Black, Robert Rowen, et al.. (2002). Amlodipine versus chlorthalidone versus placebo in the treatment of stage I isolated systolic hypertension. American Journal of Hypertension. 15(1). 31–36. 15 indexed citations

18.

Cato, Allen, John C. Cavanaugh, Harry Shi, et al.. (1998). The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin*. Clinical Pharmacology & Therapeutics. 63(4). 414–421. 54 indexed citations

19.

Chun, Alexander, et al.. (1996). Lansoprazole: administration of the contents of a capsule dosage formulation through a nasogastric tube. Clinical Therapeutics. 18(5). 833–842. 40 indexed citations

20.

Chun, Alexander, et al.. (1995). Lansoprazole: an alternative method of administration of a capsule dosage formulation. Clinical Therapeutics. 17(3). 441–447. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact